Ultragenyx wins U.S. approval for gene therapy in rare disease market
Ultragenyx has secured a key regulatory clearance in the U.S. for a treatment targeting a rare fatal disorder with no approved therapy until now. The decision clears the way for Fayuvi to enter the market after the agency had refused approval last year over manufacturing concerns.
Highlights
- Ultragenyx received U.S. FDA approval for Fayuvi, the first gene therapy for Sanfilippo syndrome Type A, targeting SGSH enzyme deficiency.
- Ultragenyx shares rose nearly 6% after the approval, reflecting market optimism about Fayuvi’s potential in a rare disease market with high unmet need.
- The FDA’s decision reverses last year’s rejection over manufacturing issues, removing a key regulatory obstacle for Ultragenyx's rare disease portfolio expansion.
Approval details and treatment scope
As reported by Reuters, citing the U.S. Food and Drug Administration, the agency has approved Ultragenyx's gene therapy for the treatment of Sanfilippo syndrome Type A, a rare disorder caused by a missing enzyme that prevents the body from breaking down heparan sulfate.The approval makes Fayuvi the first therapy for the disease. The treatment is designed to address the underlying sulfamidase, or SGSH, enzyme deficiency that leads to an abnormal buildup of heparan sulfate in the brain, resulting in progressive cell damage and neurodegeneration.
Market reaction and regulatory context
Ultragenyx shares are up nearly 6% in afternoon trading following the approval, reflecting investor optimism about the commercial potential of the therapy in a market with high unmet medical need.The clearance also marks a reversal from last year, when the U.S. Food and Drug Administration declined to approve the therapy because of manufacturing concerns. The latest decision removes a major regulatory hurdle for the company as it expands its rare disease treatment portfolio.
Our earlier article on Illumina’s turnaround outlined how the company’s improving quarterly results and a guidance upgrade helped the stock extend a sharp rebound after years of regulatory fallout, leadership upheaval, and China-related export pressure. We also noted that the recovery was reinforced by clearer evidence of demand stability and cost controls, boosting Illumina’s standing and visibility as it prepared to join the S&P 500.
Latest Argenx News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
